CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cryoport, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.98+0.14 (+0.83%)
Close on Oct 19, 2026
- Market cap
- $856.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cryoport, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Aggregate of reportable segment | $176.18M | $156.77M | $168.66M | $242.45M | – | – | – | – | 100.0% | +12.4% |
| Life Sciences Services | $101.03M | $85.34M | $81.19M | – | – | – | – | – | 57.3% | +18.4% |
| Life Sciences Products | $75.15M | $71.43M | $87.47M | – | – | – | – | – | 42.7% | +5.2% |
| Global Bioservices [Member] | – | – | – | – | – | – | $3.03M | – | – | – |
| Global Logistics Solutions | – | – | – | $237.28M | $222.61M | $78.70M | $33.94M | $19.63M | – | – |
| Life Science Supply Chain Solutions | – | $156.95M | $145.78M | $135.18M | – | – | – | – | – | – |
| Life Science Systems | – | $71.43M | $87.47M | $102.10M | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Global Bioservices [Member] | – | – | – | – | – | – | $437.12K | – | – |
| Global Logistics Solutions | – | – | – | – | – | – | -$18.11M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Service | $96.50M | $82.04M | $79.49M | $133.88M | $119.07M | $55.30M | $33.94M | – | 54.8% | +17.6% |
| Product | $79.68M | $74.73M | $89.17M | $103.40M | $103.54M | $23.40M | – | – | 45.2% | +6.6% |
| BioLogistics Solutions | $78.14M | $67.02M | $65.91M | $124.80M | – | – | – | – | 44.4% | +16.6% |
| BioStorage/BioServices | $18.36M | $15.03M | $13.59M | $9.08M | – | – | – | – | 10.4% | +22.2% |
| Biopharmaceutical | – | – | $192.58M | $193.88M | $180.20M | – | – | $16.48M | – | – |
| Animal Health | – | – | $30.38M | $33.47M | $33.35M | – | – | $976.00K | – | – |
| Reproductive Medicine | – | – | $10.29M | $9.93M | $9.05M | – | – | $2.17M | – | – |
| Global Biostorage [Member] | – | – | – | – | – | – | $3.03M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $131.26M | $113.55M | $117.90M | $128.21M | $120.27M | $49.56M | $28.80M | $17.88M | 74.5% | +15.6% |
| Europe, the Middle East, and Africa (EMEA) | $25.13M | $27.02M | $27.65M | $66.91M | $59.33M | $20.32M | $4.52M | $1.37M | 14.3% | -7.0% |
| Asia Pacific (APAC) | $19.78M | $16.20M | $23.12M | $42.16M | $43.00M | $8.83M | $618.00K | $384.00K | 11.2% | +22.1% |
From the segment and revenue-disaggregation notes of Cryoport's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.